Hui Cai
Corporate Officer/Principal presso WUXI APPTEC CO., LTD.
Profilo
Hui Cai is currently the VP-Corporate Alliances & Communications at WuXi AppTec Co., Ltd.
Prior to this, Dr. Cai held the position of Vice President-Corporate Development at HUYA Bioscience International LLC and President at Inflexion BioPartners, Inc. Dr. Cai's education includes a doctorate from The Scripps Research Institute, undergraduate and graduate degrees from Peking University, and an MBA from the University of California San Diego.
Posizioni attive di Hui Cai
Società | Posizione | Inizio |
---|---|---|
WUXI APPTEC CO., LTD. | Corporate Officer/Principal | - |
Precedenti posizioni note di Hui Cai
Società | Posizione | Fine |
---|---|---|
Inflexion BioPartners, Inc. | President | - |
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Formazione di Hui Cai
The Scripps Research Institute | Doctorate Degree |
Peking University | Graduate Degree |
University of California San Diego | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
WUXI APPTEC CO., LTD. | Health Technology |
Aziende private | 2 |
---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
Inflexion BioPartners, Inc. |
- Borsa valori
- Insiders
- Hui Cai